------------------- CUSIP No. 452327109 13 G Page 24 of 25 Pages ------------------- -------------------Venrock Associates • February 14th, 2001 • Laboratory analytical instruments
Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13G is being filed on behalf of each of the undersigned.
EXHIBIT 3 Page 62 of 70Stockholders' Agreement • November 19th, 1996 • Venrock Associates • Pharmaceutical preparations • Delaware
EXHIBIT 2 Page 23 of 70Venrock Associates • November 19th, 1996 • Pharmaceutical preparations • Delaware
CUSIP No. 452327109 13G Page 26 of 27 PagesVenrock Associates • February 14th, 2002 • Laboratory analytical instruments
Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13G is being filed on behalf of each of the undersigned.
Exhibit 99.1 ------------Exhibit 99 • February 14th, 2001 • Venrock Associates • Services-commercial physical & biological research
Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13G is being filed on behalf of each of the undersigned.
Page 21 of 21 pagesVenrock Associates • February 14th, 2001 • Services-computer programming services
Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13G is being filed on behalf of each of the undersigned.
SIRNA THERAPEUTICS, INC. WARRANT TO PURCHASE _________ SHARES OF COMMON STOCKVenrock Associates • January 4th, 2005 • Pharmaceutical preparations • Delaware
THIS CERTIFIES THAT, for value received, _______________and its assigns are entitled to subscribe for and purchase ___shares (as adjusted pursuant to Section 4 hereof, the “Shares”) of the fully paid and nonassessable common stock, par value $0.01 per share (“Common Stock”), of Sirna Therapeutics, Inc., a Delaware corporation (the “Company”), at the price of $2.52 per share (such price and such other price as shall result, from time to time, from the adjustments specified in Section 4 hereof is herein referred to as the “Warrant Price”), subject to the provisions and upon the terms and conditions set forth herein and in the Warrant Exchange Agreement, dated as of even date herewith, by and among the Company and the other parties thereto. As used herein, the term “Date of Grant” means December 30, 2004. As used herein, the term “Warrant” shall be deemed to include any warrants issued in exchange or upon transfer or partial exercise of this Warrant unless the context clearly requires oth
AGREEMENTAgreement • August 2nd, 2004 • Venrock Associates • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13D/A is being filed on behalf of each of the undersigned.
AGREEMENTAgreement • September 9th, 2009 • Venrock Associates • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13G is being filed on behalf of each of the undersigned.
AMENDMENT NO. 1 TO COMMON STOCK AND WARRANT PURCHASE AGREEMENTCommon Stock and Warrant Purchase Agreement • May 11th, 2004 • Venrock Associates • Pharmaceutical preparations • Delaware
This Amendment (the “Amendment”) to that certain Common Stock and Warrant Purchase Agreement, dated as of February 11, 2003, by and among Sirna Therapeutics, Inc. (formerly known as Ribozyme Pharmaceuticals, Inc.), a Delaware corporation (the “Company”), and the investors listed on Exhibit A thereto (the “Agreement”), is made as of May 10, 2004, by and among the Company and the parties to the Agreement listed on the signature pages hereto, each of which is herein referred to as an “Investor.” Capitalized terms not defined herein shall have the meanings ascribed to them in the Agreement.
TERMINATION AGREEMENTTermination Agreement • May 11th, 2004 • Venrock Associates • Pharmaceutical preparations • Delaware
This TERMINATION AGREEMENT (the “Agreement”) is made this 10th day of May, 2004, by and among DLJ Capital Corporation, Sprout Capital IX, L.P., Sprout Entrepreneurs’ Fund, L.P., Sprout IX Plan Investors, L.P., Venrock Associates, Venrock Associates III, L.P., Venrock Entrepreneurs Fund III, L.P., Oxford Bioscience Partners IV L.P. and mRNA Fund II, L.P. (each an Investor, and, collectively, the “Investors”).
AGREEMENTAgreement • November 25th, 2002 • Venrock Associates • Services-prepackaged software
Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13D is being filed on behalf of each of the undersigned.
AGREEMENTVenrock Associates • February 14th, 2003 • Services-prepackaged software
Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13G is being filed on behalf of each of the undersigned.
AGREEMENTAgreement • February 14th, 2007 • Venrock Associates • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13G/A is being filed on behalf of each of the undersigned.
AGREEMENTAgreement • February 14th, 2014 • Venrock Associates • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13G/A is being filed on behalf of each of the undersigned.
AGREEMENTAgreement • February 14th, 2006 • Venrock Associates • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13G is being filed on behalf of each of the undersigned.
Page 21 of 21 pagesVenrock Associates • February 14th, 2001 • Laboratory analytical instruments
Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13G is being filed on behalf of each of the undersigned.
AGREEMENTVenrock Associates • February 14th, 2005 • Orthopedic, prosthetic & surgical appliances & supplies
Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13G is being filed on behalf of each of the undersigned.
AGREEMENTAgreement • February 14th, 2003 • Venrock Associates • Radio & tv broadcasting & communications equipment
Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13G is being filed on behalf of each of the undersigned.
AGREEMENTAgreement • February 16th, 2010 • Venrock Associates • Services-business services, nec
Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13G is being filed on behalf of each of the undersigned.
SIRNA THERAPEUTICS, INC. WARRANT TO PURCHASE ________ SHARES OF COMMON STOCKVenrock Associates • January 4th, 2005 • Pharmaceutical preparations • Delaware
THIS CERTIFIES THAT, for value received, ___ and its assigns are entitled to subscribe for and purchase ___shares (as adjusted pursuant to Section 4 hereof, the “Shares”) of the fully paid and nonassessable common stock, par value $0.01 per share (“Common Stock”), of Sirna Therapeutics, Inc., a Delaware corporation (the “Company”), at the price of $3.85 per share (such price and such other price as shall result, from time to time, from the adjustments specified in Section 4 hereof is herein referred to as the “Warrant Price”), subject to the provisions and upon the terms and conditions set forth herein and in the Warrant Exchange Agreement, dated as of even date herewith, by and among the Company and the other parties thereto. As used herein, the term “Date of Grant” means December 30, 2004. As used herein, the term “Warrant” shall be deemed to include any warrants issued in exchange or upon transfer or partial exercise of this Warrant unless the context clearly requires otherwise. Not
AGREEMENTAgreement • January 4th, 2005 • Venrock Associates • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13D/A is being filed on behalf of each of the undersigned.
AGREEMENTAgreement • February 14th, 2007 • Venrock Associates • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13G is being filed on behalf of each of the undersigned.
AGREEMENTAgreement • February 14th, 2006 • Venrock Associates • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13G is being filed on behalf of each of the undersigned.
AGREEMENTAgreement • February 14th, 2006 • Venrock Associates • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13G is being filed on behalf of each of the undersigned.
AGREEMENTAgreement • February 11th, 2011 • Venrock Associates • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13G is being filed on behalf of each of the undersigned.
AGREEMENTAgreement • February 14th, 2013 • Venrock Associates • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13G/A is being filed on behalf of each of the undersigned.
AGREEMENTAgreement • February 16th, 2010 • Venrock Associates • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13G is being filed on behalf of each of the undersigned.
AGREEMENTAgreement • February 14th, 2011 • Venrock Associates • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13G is being filed on behalf of each of the undersigned.
WARRANT EXCHANGE AGREEMENT by and among Sirna Therapeutics, Inc. and certain Warrantholders of Sirna Therapeutics, Inc. dated as of December 30, 2004Warrant Exchange Agreement • January 4th, 2005 • Venrock Associates • Pharmaceutical preparations
THIS WARRANT EXCHANGE AGREEMENT (this “Agreement”) is dated as of December 30, 2004, by and among Sirna Therapeutics, Inc., a Delaware corporation (the “Company”) and those warrantholders of the Company listed on Exhibit A to this Agreement (each a “Warrantholder” and collectively the “Warrantholders”) who have executed this Agreement in one or more counterparts.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 16th, 2010 • Venrock Associates • Pharmaceutical preparations
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Infinity Pharmaceuticals, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
AGREEMENTAgreement • February 14th, 2008 • Venrock Associates • Services-business services, nec
Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13G is being filed on behalf of each of the undersigned.
AGREEMENTAgreement • February 14th, 2007 • Venrock Associates • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13G is being filed on behalf of each of the undersigned.
AGREEMENTVenrock Associates • February 14th, 2005 • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13G is being filed on behalf of each of the undersigned.
AGREEMENTAgreement • February 13th, 2004 • Venrock Associates • Orthopedic, prosthetic & surgical appliances & supplies
Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13G is being filed on behalf of each of the undersigned.
